Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMBALS: Ambroxol for ALS
NCT05959850Phase 2Unknown
- Sponsor
- Florey Institute of Neuroscience and Mental Health
- Start
- Jun 2023
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ambroxol in amyotrophic lateral sclerosis (ALS), sponsored by Florey Institute of Neuroscience and Mental Health. Status: unknown.
02
Drugs
ambroxol
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT05959850.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05959850.